Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sindilimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2000039110Phase 4Recruiting
- Sponsor
- Quanzhou First Hospital
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Quanzhou First Hospital. Primary endpoint: Objective response rate. Started Oct 2020; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000039110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039110.